Wednesday - June 11, 2025
Vancouver, British Columbia – TheNewswire – June 11, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharma/biotechnology company dedicated to developing novel and effective mental health treatments, is pleased to announce the enrolment of the 85th participant in its landmark Phase 2B clinical trial evaluating MB22001 for Major Depressive Disorder (MDD). MB22001, MindBio’s proprietary, titratable... Read more
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 (titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders”) that... Read more
The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, June 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the Swedish Ethical Review Authority and the Swedish Medical Products Agency have authorized a double-blind phase 2 clinical trial studying its botanical psilocybin... Read more
Patent-protected aminated tryptamine derivatives strengthen Enveric’s leadership in next-generation mental health treatments CAMBRIDGE, Mass. / Jun 10, 2025 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a... Read more
Ketamine faces a current US drug shortage not expected to abate in the near future1 Current ketamine market estimated at $750 million and projected to reach $3.35 billion globally in 2034.2 NRx anticipates marketing ketamine for all approved uses Company anticipates priority review based on current and anticipated drug shortage NRX-100 to provide innovative, preservative-free IV ketamine formulation to eliminate benzethonium chloride preservative, in... Read more
CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today... Read more
New Intellectual Property Unlocks Potential for Sleep and CNS Therapeutics CAMBRIDGE, Mass. / Jun 03, 2025 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced the issuance of a new U.S. patent (USPTO Number 12,187,679). The patent strengthens Enveric’s... Read more
MindBio debuts app.booze-ai.com to investors in Silicon Valley Vancouver, British Columbia – TheNewswire - June 3, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharma/biotechnology company has today launched Booze AI, in Silicon Valley, debuting the world’s first AI-driven, voice-activated blood alcohol concentration (BAC) estimator for use on smartphones, tablets and computers to 150... Read more
Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine (“DMT”) and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 Cybin’s growing intellectual property portfolio comprises more than 90 granted patents and over 230 pending applications TORONTO / Jun 03, 2025 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a... Read more
Streamlined U.S.-only study design builds on Phase 2 momentum for IHL-42X in obstructive sleep apnea NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today announced that the Phase 3 component of the RePOSA clinical trial will proceed. The U.S. Food and Drug Administration (FDA) previously reviewed and authorized the protocol to... Read more
Statistically significant improvements in a preclinical model of severe chronic depression and despair Support for safe, extended, daily oral administration CAMBRIDGE, Mass. / May 28, 2025 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced positive... Read more
TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, FSD Pharma Australia Pty Ltd., that it has received approval by the human ethics review committee (HREC) in Australia for its trial entitled “A Randomized, Double-Blind Placebo... Read more
NEW YORK and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and Jan Torleif Pedersen, Chief Scientific Officer, will... Read more
VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders, recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating... Read more
New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for unmet mental health needs, today announced the finalization of its service agreement with Southern Star Research Pty Ltd ("Southern Star Research"), an award-winning, full-service Australian Contract Research Organization (CRO). This agreement marks a pivotal advancement for... Read more
VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce a non-brokered private placement for gross proceeds of $1,000,000 (the “Offering”) of units of common shares (the “Common Units”) at an issue price of $0.07 per Common Unit and units of preferred... Read more
Study is expected to deliver final device data and documentation needed for planned FDA IND submission SARASOTA, FL, May 21, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a service agreement with medical technology provider Resyca BV for a drug-device study of the formulation-specific... Read more
PALM BEACH, Fla., May 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced that that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics, will be presenting a Company update at the upcoming Wall Street Conference, taking place on May 21, 2025 in Palm Beach, FL. NRx is one of six companies... Read more
Vancouver, Canada, May 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled "Gazing Through the Crystal Ball." The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature... Read more
Enveric files provisional patent application on newly identified group of molecules CAMBRIDGE, Mass. / May 20, 2025 / Business Wire / Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that it has filed a new provisional patent application with claims to methods and... Read more
TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that it has signed an agreement with a global pharmaceutical contract research organization to prepare an IND (Investigational New Drug) application package for Lucid-21-302 (Lucid-MS) with the US FDA.... Read more
A Brighter Future for Mental Health Vancouver, British Columbia – May 19, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel and effective mental health treatments, is pleased to announce the enrolment of the 80th participant in its landmark Phase 2B clinical trial evaluating MB22001 for Major Depressive Disorder (MDD). This milestone underscores... Read more
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on ketamine for unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has extended the approval goal date for the review of its new drug application for ketamine. The new approval goal date is August 9, 2025, revised from the previous date of June 4, 2025. The extension allows... Read more
Term sheet with Universal Capital, LLC to fund HOPE Therapeutics clinic acquisition strategy Funding tied to already-announced acquisitions, with additional tranches contemplated for further growth, subject to standard due diligence Together with previously announced term sheet with a strategic investor, HOPE funding of $10.3 million is planned in the near term MIAMI, May 15, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical... Read more
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to formally announce the launch of the Phenesafe AI platform, an AI technology stack specifically designed to derive novel substituted phenethylamine molecules for patent and... Read more
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Pharmaceutical Pipeline Presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) in Arizona, United States from May 27 – 30, where Professor Michael E. Thase, MD, Professor of Psychiatry,... Read more
Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholders In January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional... Read more
NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended March 31, 2025. “The third quarter of 2025 represents a pivotal period of progress for Incannex as we continue to execute on our IHL-42X development... Read more
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into an agreement with Frontage Laboratories, a global full-service CRO (contract research organization),... Read more
Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA. End-of-study follow-up assessments on track for completion by May 17, 2025. Topline results expected in July 2025. NEW YORK and MELBOURNE, Australia, May 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today provided an... Read more
KetaVault™ to Provide Partners Unprecedented Access to PharmaTher's Extensive Regulatory, Manufacturing, and Clinical Ketamine Data, Aiming to Expedite New Therapies and Market Entry TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on the research and commercialization of ketamine for unmet medical needs, today announced the launch of&... Read more
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders, recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary... Read more
Corporate, Business and Product Development Highlights: Unveiled EVM401 Series with new U.S. Patent for mescaline derivative compounds Added to suite of intellectual property for EB-003, a neuroplastogen targeting undertreated mental health indications Signed two licensing agreements for cannabinoid-COX-2 conjugate compounds, with potential to target joint pathologies, such as osteoarthritis and rheumatoid arthritis Announced closing of $5 million public offering... Read more
BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) Findings highlight BMB-101’s potential to address critical gaps in SUDEP prevention NEW YORK and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on... Read more
Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwide Kadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this space Dr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA... Read more
NEW YORK / May 13, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at the 2025 RBC Capital Markets Global Healthcare Conference: 2025 RBC Capital Markets Global Healthcare Conference Format: Fireside Chat and 1x1 Meetings Date:... Read more
First Clinic Targeted to Open Q4, 2025 in the U.S. VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has entered into share exchange agreements to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. (“NIC”) (the... Read more
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that dosing of drug has completed in 90-day oral toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS) for Multiple Sclerosis (“MS”). These studies were commissioned to provide data to support... Read more
Patent publication in Europe strengthens Clearmind’s global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the official publication of a... Read more
Vancouver, British Columbia – TheNewswire - May 12, 2025 – MindBio Therapeutics Corp. (the “Company” or “MindBio”) (Frankfurt: WF6), (CSE:MBIO), a clinical stage biopharma company targeting depressive illnesses currently in multiple late stage Phase 2B clinical trials is pleased to announce that as a result of strong support from its lenders, shareholders and investors, it has initiated a proposed package of financing and debt settlements which should position... Read more
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 month data follow-up over the course of 2025. Plans to start Phase III registration trial in H1 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026 (US prevalence 20,000 pat... Read more
Newly issued patent includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041 Cybin’s growing intellectual property portfolio comprises more than 80 granted patents and over 230 pending applications Patient dosing continues in APPROACH, Cybin’s first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder (“MDD”) Second Phase 3 study, EMBRACE,... Read more
Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reduction Full response to the IND hold on track for submission in mid-2025 Cash, cash equivalents, other financial assets and marketable securities of $315.3 million as of March 31, 2025 DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing... Read more
Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026 Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama Company to host a conference call today at 8:00 a.m. EDT NEW YORK / May 08, 2025 / Business Wire... Read more
Highlights: 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June Phase 3 COMP006 in TRD on track for 26-week data second half of 2026 Cash position of $260.1 million at March 31, 2025 Conference call on May 8 at 8:00 am ET (1:00 pm UK) LONDON & NEW YORK / May 08, 2025 / Business Wire / Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based... Read more
MIAMI, May 6, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced that it will host an investor event at the Mar-A-Lago Club in Palm Beach, Florida, on Thursday, May 8, 2025, at the invitation of club members. This discussion is being held to review previously-disclosed... Read more
Patent expected to be Orange Book listable, if granted NRX-100, preservative free, IV ketamine, is designed to avoid potential toxicity concerns linked to benzethonium chloride, used in currently available formulations of ketamine Filing strengthens NRx's leadership in advancing safe and effective treatments for suicidal depression WILMINGTON, Del., May 5, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"),... Read more
The Company is now recognized by the U.S. FDA to support the cross-border supply of GMP MDMA and psilocybin to authorized entities in the United States. Vancouver, British Columbia--(Newsfile Corp. - May 5, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocybin, has received its U.S. FDA Establishment Identifier (FEI) number—a key regulatory step for engaging in FDA filings... Read more
Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26’s potential... Read more
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2025. All figures are reported in Canadian dollars. The Company’s full set of... Read more
